
The development of biomarker-driven therapies for nonsmall cell lung cancer (NSCLC) has the potential to significantly improve treatment outcomes. However, it also brings new challenges for equitable care delivery. Interdisciplinary communication and coordination have become crucial for patients with or suspected to have lung cancer, as biomarker testing plays a vital role in their diagnosis and treatment. A comprehensive guide has been released, offering insights into the current state of biomarker testing for NSCLC. The guide highlights the integration of biomarker testing within the diagnostic process and provides best practices and common pitfalls through case scenarios, aiming to enhance the success and timeliness of biomarker testing.
Like
Save
Share